Coelho, Teresa
Adams, David
Conceição, Isabel
Waddington-Cruz, Márcia
Schmidt, Hartmut H.
Buades, Juan
Campistol, Josep
Berk, John L.
Polydefkis, Michael
Wang, Jing Jing
Chen, Jihong
Sweetser, Marianne T.
Gollob, Jared
Suhr, Ole B.
Funding for this research was provided by:
Alnylam Pharmaceuticals (-)
Article History
Received: 30 September 2019
Accepted: 4 May 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: This study was conducted according to the guidelines of the International Conference on Harmonisation, the World Health Organization Declaration of Helsinki, and the Health Insurance Portability and Accountability Act of 1996. Written informed consent was obtained from all participants in the study. The study protocol was approved by local Institutional Review Boards and Ethics Committees, and all subsequent protocol amendments underwent the same approval procedure.
: Not applicable.
: TC reports compensation for training from Pfizer Pharmaceuticals and Alnylam Pharmaceuticals Inc., and compensation for travel from Pfizer Pharmaceuticals, Alnylam Pharmaceuticals Inc., and IONIS Pharmaceuticals. DA reports grants from Alnylam Pharmaceuticals Inc., and personal fees from Pfizer Pharmaceuticals and Alnylam Pharmaceuticals Inc. outside the submitted work. IC acknowledges financial support as a primary investigator for FoldRx Pharmaceuticals/Pfizer Inc., Alnylam Pharmaceuticals Inc., and IONIS Pharmaceuticals, and serves on the Transthyretin Amyloidosis Outcome Survey (THAOS) scientific advisory board. MWC received honorarium from NHI, Prothena, FoldRx, Akcea Therapeutics, Pfizer Pharmaceuticals, Alnylam Pharmaceuticals Inc., PTC, and Genzyme for travel expenses related to presentations at medical meetings, and for acting as a consultant and as a principal investigator in clinical trials. HHS reports grants and consulting fees from Alnylam Pharmaceuticals Inc. outside the submitted work. JBu reports personal fees from Alnylam Pharmaceuticals Inc. during the conduct of the study for serving as a principal investigator. JCo has nothing to disclose. JBe reports serving as a study investigator for IONIS Pharmaceuticals and Pfizer Pharmaceuticals, and consultant for Intellia Therapeutics Inc. and Corino Therapeutics Inc. outside the submitted work. MP reports grants from Alnylam Pharmaceuticals Inc. during the conduct of the study and honorarium following completion of the study. JJW, JCh, MTS, and JG are all Alnylam employees. OBS reports personal fees from Alnylam Pharmaceuticals Inc. during the conduct of the study, personal fees and non-financial support from Pfizer Pharmaceuticals, and personal fees from Prothena Pharmaceuticals and Intellia Therapeutics, Inc. outside the submitted work.